E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver

10.1158/0008-5472.CAN-11-2196

10.1101/gad.12.15.2245

Frolov, 2004, Molecular mechanisms of E2F-dependent activation and pRB-mediated repression, J Cell Sci, 117, 2173, 10.1242/jcs.01227

10.1038/ncb2309

10.1172/JCI81542

10.1016/S1534-5807(02)00190-9

10.1074/jbc.M802418200

10.1016/S0960-9822(98)70386-0

10.1126/science.3513311

10.1172/JCI116663

Borghi, 2016, [The new lipid-lowering drugs: focus on monoclonal antibodies], G Ital Cardiol (Rome), 17, 14S

10.1074/jbc.M112.380618

10.1074/jbc.M508582200

10.1172/JCI16001

10.1172/JCI66028

10.1002/hep.27121

10.1194/jlr.M038331

Fon Tacer, 2011, Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation, J Lipids, 2011, 10.1155/2011/783976

Arguello, 2015, Recent insights on the role of cholesterol in non-alcoholic fatty liver disease, Biochim Biophys Acta, 1852, 1765, 10.1016/j.bbadis.2015.05.015

10.1016/j.tem.2015.11.008

10.1016/j.plipres.2012.11.002

Poirier, 2013, The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol, Drug Des Devel Ther, 7, 1135

10.1161/01.ATV.0000134621.14315.43

10.1194/jlr.M052969

10.1172/JCI16452

10.1002/path.4630

10.1161/ATVBAHA.108.181586

10.1194/jlr.M400396-JLR200

10.1126/science.1247005

Salmon, 2006, Production and titration of lentiviral vectors, Curr Protoc Neurosci, Chapter 4, 10.1002/0471142301.ns0421s37

10.1172/JCI41636

10.1002/embr.201338126

10.1002/hep.26316

10.1172/JCI34314

Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5